Safety Profile of New Therapies

Opinion
Video

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.

Video content above is prompted by the following:

  • Based on the clinical trial data, how do you view the safety profiles of faricimab and aflibercept 8 mg?
  • Does the long-term safety profile of aflibercept 2 mg increase your confidence in the safety of aflibercept 8 mg?
  • Does the increased volume of aflibercept 8 mg raise concerns about the potential for elevated intraocular pressure? How do you evaluate and address this in clinical practice?

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
2 experts in this video
© 2025 MJH Life Sciences

All rights reserved.